Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06362369
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-03-21
Brief Title:
A Study of Oral 7HP349 Alintegimod in Combination with Ipilimumab Followed by Nivolumab Monotherapy
Sponsor:
7 Hills Pharma LLC
Organization:
7 Hills Pharma LLC
Study Overview
Official Title:
A Phase 1b2a Multi-Center Dose Escalation and Reference Regimen-Controlled Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 Alintegimod in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open-label Phase Ib Part A dose escalation followed by a blinded randomized multi cohort Phase 2a Part B comparison of combination vs reference regimens
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Detailed Description:
This Phase study is designed to evaluate the safety tolerability and preliminary efficacy of oral Alintegimod Alintegimod alone and then in combination with ipilimumab for followed by nivolumab monotherapy cycles All patients will receive nivolumab after completion of treatment with Alintegimod plus ipilimumab combination therapy to continue nivolumab treatment until the end of study 12 months unless progression or toxicity result in early termination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None